Dietary Supplementation and Cognitive Functions in the Elderly
ESPINS
Evaluation of Dietary Supplementation With Hesperidin and Proanthocyanidins on Cognitive and Motor Functions in Elderly Subjects
1 other identifier
interventional
36
1 country
1
Brief Summary
In recent years, globally, there has been a growth in both the size and the proportion of older adults in the world population. The World Health Organization (WHO) has estimated that by 2030, 1 in 6 people will be 60 years of age or older, and that by 2050, the population of older adults will reach 2.1 billion. The population of older adults (over 80 years) will triple to 426 million by 2050. In particular, Italy represents the second country with the oldest population in the world. Age-related evolution is a gradual and continuous process involving a series of physical and cognitive changes, which, however, has no real 'onset' age. In fact, rather than chronological age, the concept of 'elderly' is based on the individual's degree of self-sufficiency and independence. From a biological point of view, ageing is the set of changes at the molecular and cellular level that occur over time and lead to multi-system functional impairment. It is a process directly related to frailty, falls, and disability. An important factor in counteracting frailty is nutritional intake. Humans ingest approximately 500 g of chemical compounds daily through their diet, most of which are components of plants or vegetables in general. In addition to the well-known macronutrients (proteins, fats, and carbohydrates) and micronutrients (minerals and vitamins), the plant world provides other elements, such as phenols, terpenes, terpenoids, alkaloids, purines, pyrimidines, nucleic acids, and steroids, that exert powerful biological activities. These components are generically called phytochemicals. Epidemiological studies have established that diets rich in plant-based foods help prevent many diseases, such as cardiovascular, metabolic, neurovegetative, and inflammatory diseases. Phytochemical compounds are an extremely diverse set of elements that, when taken at significant levels, have a protective effect on human health. These substances exert various biological functions, such as antioxidant activity, modulation of detoxifying enzymes, stimulation of the immune system, reduction of platelet aggregation, modulation of hormone metabolism, reduction of blood pressure, and antibacterial and antiviral activity. Among the phytochemical compounds, flavonoids represent a category of polyfunctional substances with high bioactivity, comprising more than 5000 compounds. They possess biochemical properties of functional interest in the nutritional and therapeutic fields; for example, rutin, diosmin, and hesperidin are present in some pharmaceutical specialties; flavonoids from ginkgo biloba, hawthorn, and red vine are the main components of many phytotherapeutic extracts. Flavonoids have been shown to play an important role in cardioprotection. Furthermore, in neuroprotection, anthocyanin-rich fruits play a protective role against age-related decline in cognitive functions. However, few studies have evaluated the effect of hesperidin and proanthocyanidins on motor, cognitive, and functional aspects in the elderly. Altemor® is a food supplement based on micronized diosmin, hesperidin, and herbal extracts that has an important integrative supporting action in optimising blood microcirculation. The aim of the study is to evaluate the contribution of dietary supplementation with Altemor® on cognitive function, balance, fatigue, and some domains of quality of life in elderly subjects.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started May 2024
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 2, 2024
CompletedFirst Posted
Study publicly available on registry
April 8, 2024
CompletedStudy Start
First participant enrolled
May 2, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 15, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
February 17, 2025
CompletedMarch 27, 2025
March 1, 2025
7 months
April 2, 2024
March 26, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Trial Making Test (TMT)
The TMT measures flexibility of thinking on a visual-motor sequencing task. It consists of two parts, A and B, where 25 circles distributed over a sheet of paper. In Part A, the circles are numbered 1 - 25, and the patient should draw lines to connect the numbers in ascending order. In Part B, the circles include both numbers (1 - 13) and letters (A - L); as in Part A, the patient draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letters (i.e., 1-A-2-B-3-C, etc.). Results for both TMT A and B are reported as the number of seconds required to complete the task; therefore, higher scores reveal greater impairment. Trail A: Average 29 seconds, Deficient \> 78 seconds, Rule of Thumb Most in 90 seconds Trail B: Average 75 seconds, Deficient \> 273 seconds, Rule of Thumb Most in 3 minutes
Change from Baseline TMT at 8 and 16 weeks
Secondary Outcomes (7)
Short Physical Performance Battery (SPPB)
Change from Baseline SPPB at 8 and 16 weeks
HandGrip Strenght Test (HGST)
Change from Baseline HGST at 8 and 16 weeks
Silver Index (SI)
Change from Baseline SI at 8 and 16 weeks
Mental Deterioration battery (MDB)
Change from Baseline MDB at 8 and 16 weeks
Hospital Anxiety and Depression Scale (HADS)
Change from Baseline HADS at 8 and 16 weeks
- +2 more secondary outcomes
Study Arms (3)
G-Alt12
EXPERIMENTALG-Alt12 patients, without making any changes to their current drug routine, will take 1 stick per day of Altemor® for 8 weeks, go for a period of 4 weeks without taking the food supplement, and then take 2 sticks per day of Altemor® for another 8 weeks.
G-Alt21
EXPERIMENTALG-Alt21 patients, without making any changes to their current medication routine, will take 2 sticks per day of Altemor® for 8 weeks, do a 4-week period without taking the dietary supplement, and then take 1 stick per day of Altemor® for another 8 weeks.
G-Con
NO INTERVENTIONG-Con patients will undergo clinical and instrumental evaluations at the study endpoints
Interventions
Taking a dietary supplement with micronised diosmin, hesperidin and plant extracts 1 or 2 sticks per day, as per the study design.
Eligibility Criteria
You may qualify if:
- Body mass index (BMI) between 25 and 32 kg/m2
- Non-smoker
- Cognitive ability to carry out simple orders and to understand the physiotherapist's instructions \[assessed by the Mini Mental State Examination (correct score between 22 and 27)\]
- Independence in instrumental activities of daily living \[assessed by the Instrumental Activities of Daily Living (score \< 5)
- Medication stability of at least 12 months for taking any medication for hypertension, hyperlipidemia, inflammation, hypercholesterolemiaand hypercoagulation;
- Ability to walk independently or with little assistance;
- Ability to understand and sign informed consent.
You may not qualify if:
- Previous history of stroke and/or myocardial infarction;
- Presence of altered mood \[assessed by the Hospital Anxiety and Depression Scale (score ≤ 8)\].
- Presence of kidney or intestinal disease, pancreatitis, diabetes or any other endocrine disorder
- Presence of demyelinating and dysmyelinating diseases;
- Presence of anticoagulant or antiplatelet drugs;
- Systemic, neurological or cardiac diseases that make walking unsafe or cause motor deficits;
- Oncological pathologies;
- Vegetarian diet, regular intake of supplements including fish oil, fatty acids, vitamins and minerals
- Orthopaedic or postural problems;
- Presence of plantar ulcers;
- Partial or total amputation of foot segments.
- Inability to provide informed consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Fondazione Policlinico Universitario A. Gemelli IRCCS
Roma, RM, 00168, Italy
Related Publications (1)
Giovannini S, Lauria A, Malizia AM, Lama E, Morciano N, Biscotti L, Loreti C, Castelli L. The Effectiveness of Hesperidin, Diosmin and Proanthocyanidins Nutritional Supplementation on Cognitive and Motor Functions in Older Adults: A Pilot Randomized Control Study. J Am Nutr Assoc. 2026 Jan;45(1):24-36. doi: 10.1080/27697061.2025.2526600. Epub 2025 Jul 22.
PMID: 40694049DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Silvia Giovannini, MD, PhD
Fondazione Policlinico Universitario A. Gemelli, IRCCS
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal investigator
Study Record Dates
First Submitted
April 2, 2024
First Posted
April 8, 2024
Study Start
May 2, 2024
Primary Completion
November 15, 2024
Study Completion
February 17, 2025
Last Updated
March 27, 2025
Record last verified: 2025-03
Data Sharing
- IPD Sharing
- Will not share